Pharmaceutical & Life Sciences News

Celgene to Acquire Juno for $9 Billion to Add Cancer Treatments

Jan. 22, 2018, 5:07 PM

Celgene Corp. agreed to buy Juno Therapeutics Inc. for about $9 billion, one of its largest deals ever, in a bid to expand in the increasingly competitive landscape of cutting-edge cancer treatments.

With Juno, Celgene will gain research into a novel class of therapies known as CAR-T that use the body’s own immune system to fight cancer. The Summit, N.J.-based company will pay $87 a share in cash, according to a statement Monday. That’s 91 percent above Juno’s closing price Jan. 16, the last trading day before the Wall Street Journal reported the companies were in talks.

Celgene is doubling...

To read the full article log in. To learn more about a subscription click here.